NorthStrive Biosciences Announces Positive Phase III Drug Discovery Results
NorthStrive Biosciences announced that four compounds significantly increased ANT1 expression in human skeletal muscle cells. The results support the development of muscle-preserving therapeutics.
View filing at SEC.gov →